4
Orphan Designations
0 approved, 4 designated
0
FDA Approvals
0
Active Trials
200 recruiting
4
Rare Diseases
across 11 areas
0
News (30d)
Quiet
Sugen, Inc. is a company with 4 orphan drug designations across 4 rare diseases.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| Kaposi's sarcoma | 3-(3,5-dimethyl-1H-2ylmethylene)-1,3-dihydro-indol-2-one | Des.TrialAppr. |
| malignant glioma | N-[4-(trifluoromethyl)phenyl] 5 methylisoxazole-4-carboxamide | Des.TrialAppr. |
| ovarian cancer | N-[4-(trifluoromethyl)phenyl]-5-methylisoxazole-4-carboxamide | Des.TrialAppr. |
| von Hippel-Lindau disease | 3-(3,5-Dimethyl-1H-2ylmethylene)-1,3-dihydro-indol-2-one | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
13
overlap in 2+ diseases
0/4
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
13
overlap in 2+ diseases
0/4
candidate diseases
0
avg importance: 0
0
affecting portfolio